Reference : Metformin + saxagliptin for type 2 diabetes.

	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Pharmacy, pharmacology & toxicology Human health sciences : Endocrinology, metabolism & nutrition
	To cite this reference:	http://hdl.handle.net/2268/117702

Title :	Metformin + saxagliptin for type 2 diabetes.
Language :	English
Author, co-author :	SCHEEN, André [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques]
Publication date :	2012
Journal title :	Expert Opinion on Pharmacotherapy
Publisher :	Ashley Publications Ltd
Volume :	13
Issue/season :	1
Pages :	139-46
Audience :	International
ISSN :	1465-6566
e-ISSN :	1744-7666
City :	London
Country :	United Kingdom
Keywords :	[en] DPP-4 inhibitor ; Saxagliptin ; Renal insufficiency ; Metformin ; Lactic acidosis ; Type 2 diabetes mellitus
Abstract :	[en] INTRODUCTION: Metformin is considered as the first-line drug therapy for the management of type 2 diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors, by promoting insulin secretion and reducing glucagon secretion in a glucose-dependent manner, offer new opportunities for oral therapy after failure of metformin. AREAS COVERED: An updated review of the literature demonstrates that saxagliptin, a DPP-4 inhibitor, and metformin may be administered together, separately or in fixed-dose combination (FDC), either as saxagliptin added to metformin or as initial combination in drug-naive patients. Both compounds exert complementary pharmacodynamic actions leading to better improvement in blood glucose control (fasting plasma glucose, postprandial glucose, HbA1c) than either compound separately. Adding saxagliptin to metformin monthotherapy results in a consistent, sustained and safe reduction in HbA1c levels. Tolerance is excellent without hypoglycemia or weight gain. EXPERT OPINION: The combination saxaglitpin plus metformin may be used as first-line or second-line therapy in the management of type 2 diabetes, especially as a valuable alternative to the classical metformin-sulfonylurea combination.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/117702
DOI :	10.1517/14656566.2012.642867

	File(s) associated to this reference
	Fulltext file(s): File Commentary Version Size Access Open access Metformin+saxagliptin for type 2 diabetes.pdf Author preprint 379.9 kB View/Open

All documents in ORBi are protected by a user license.

 

© ULg Library Network |  Feedback |  ORBi legal notices

Dspace v1.5